

**ATTENTION EARLY-CAREER RESEARCHERS WORKING IN ATTR!**

# 1<sup>st</sup> Annual ATTR Early-Career Research Forum

## CALL FOR ABSTRACTS

**Abstract Submission Deadline: Monday, August 26, 2024**


**Two ATTR Young Investigator Research Awards: \$100,000 each**

An Academic Colloquium Dedicated to Recognizing, Inspiring, and Equipping Physician Scientist Fellows and Early-Career Faculty Conducting High-Impact Clinical or Translational Research in Transthyretin-mediated Amyloidosis (ATTR).

The **ATTR Early-Career Research Forum** is a unique educational and career-catalyzing opportunity for US-based young investigators conducting clinical or translational research in transthyretin-mediated amyloidosis (ATTR). Using a strategic synergy of expert mentoring, peer-to-peer and peer-to-expert collaborations, structured feedback, and preeminent national exposure, this rigorous and highly selective academic research forum will empower early-career researchers with the knowledge, skills, confidence, support, and community-building requisite for successful and longitudinal careers in ATTR research.



## Forum Co-Chairs



**Sami Khella, MD**  
Co-Founder, Penn  
Amyloidosis Center  
Professor of Neurology  
University of Pennsylvania  
School of Medicine  
Philadelphia, PA



**Noel Dasgupta, MD, FACC**  
Indiana University Amyloidosis  
Research Group  
Associate Professor of  
Clinical Medicine  
Indiana University School of Medicine  
Indianapolis, IN



**Ahmad Masri, MD, MS**  
Director, Cardiac  
Amyloidosis Program  
Assistant Professor of Medicine  
Oregon Health & Science  
University  
Portland, OR



US-based fellows or early-career faculty conducting clinical or translational research across the ATTR disease continuum.

- **Fellows:** MD +/- PhD currently (at time of abstract submission) enrolled in an ACGME-accredited fellowship program.
- **Early-Career Faculty:** MD +/- PhD within 5 years of first faculty appointment (at time of abstract submission).

## FORUM FORMAT & SCORING

The Expert Committee will review all submitted abstracts, in a blinded fashion, and the top 4 young investigators will be selected to present their work during the Virtual Forum in late-September 2024. Pre-meeting abstract scoring will be predicated on the following categorical criteria:

- **Scientific Rigor** – is the study hypothesis reasonable? Was the methodology and research design appropriate and/or validated to establish data-driven conclusions?
- **Real-World Impact** – is the hypothesis relevant to current and prevailing gaps in scientific knowledge or clinical practice? Is it innovative? Does testing the hypothesis have the potential to add something new to the field and/or advance the disease management paradigm?
- **Overall Quality** - is the abstract professionally-written and cohesive throughout? Were principal study questions and conclusions clearly articulated? Were the conclusions applied to real-world practice in a meaningful way?

The Virtual Forum will be conducted via Zoom and young investigator presentations will be formal and structured at 15 minutes each – comprised of 9 minutes of content (wherein they will articulate, using PowerPoint slides, their research rationale, methodologies, results, and conclusions) and 6 minutes of dynamic Q&A with the Expert Committee. Each of the final four young investigators will be evaluated and scored by the Committee based on the aforementioned categorical criteria plus:

- **Podium Presentation and Q&A Performance** – did the presenter clearly and confidently communicate the study hypothesis, methodology, and conclusions within the predefined time limits? Was the PowerPoint presentation polished and professional? Did the slides add clarity to key points? Was the presenter able to provide prompt and cogent responses to expert questions and engage in an evidence-based dialogue?

## AWARDS & OPPORTUNITIES

*The top 2 performers, as determined by our Expert Committee of Co-Chairs, will both receive the following:*

- **\$100,000 ATTR Young Investigator Research Award** (each) issued directly to their institution to bolster and further their ongoing ATTR research efforts.
- **Preferred invitation to share research findings and progress** to-date on the national stage during an ATTR-focused independent satellite symposium **at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting.**



## HOW (& WHAT) TO SUBMIT

All abstracts can be submitted at [www.cornerstonemeded.com/ATTR-ECRF](http://www.cornerstonemeded.com/ATTR-ECRF) and should conform to the following format parameters:

- Submit as Microsoft Word document saved with young investigator's name (i.e., "Title of abstract\_Jane Smith")
- Maximum of 750 words and no more than 5 high-resolution ( $\geq 300$  dpi) figures/tables/graphics
- 10-12-point Calibri or Times New Roman font; 1-inch margins
- Organize abstracts using the following standard sections:
  - Disclosures - relevant financial relationships or conflicts of interest
  - Background – a brief statement of the study purpose and rationale
  - Methods – a concise overview of methodology
  - Results – a clear delineation of findings
  - Conclusions – a focused description of distinct takeaways

**Abstract Submission Deadline:**  
**Monday, August 26, 2024**

**Two ATTR Young Investigator  
Research Awards:**  
**\$100,000 each**

## ABSTRACT SELECTION & NOTIFICATION

Confirmation of abstract receipt will be provided to each young investigator by email shortly after submission. *The young investigators earning the top 4 scores, as determined by the Expert Committee, will be notified by **September 2nd** and invited to present their work during the Virtual Forum held on **September 23, 2024**.*

## CONNECT WITH US

@ [www.cornerstonemeded.com/ATTR-ECRF](http://www.cornerstonemeded.com/ATTR-ECRF)

✉ [info@cornerstonemeded.com](mailto:info@cornerstonemeded.com)

✕ @Cornerstone\_CME / @MasriAhmadMD



**Scan the QR code to Submit**

or visit [www.cornerstonemeded.com/ATTR-ECRF](http://www.cornerstonemeded.com/ATTR-ECRF)



The ATTR-ECRF is jointly provided by Cornerstone Medical Education, LLC and American Academy of CME, Inc., in partnership with the Amyloidosis Research Consortium, Mackenzie's Mission, and their Amyloidosis Speakers Bureau.

This activity is supported by an independent educational grant from AstraZeneca and Alexion, AstraZeneca Rare Disease